Nov 30, 2020
BIVDA Chief Executive Doris-Ann Williams has commented on the launch of the Medicines and Diagnostic Manufacturing Transformation Fund. “We welcome the announcement of the Medicines and Diagnostic Manufacturing Transformation Fund by the Prime Minister today. The lessons the country has learned during this difficult year in pandemic response must not be forgotten, and the innovations should be used to improve our diagnostic testing system for non-COVID illnesses including cancer...
Read More
Nov 25, 2020
BIVDA Comments on Spending Review 2020 BIVDA has commented on Chancellor Rishi Sunak’s speech to the House of Commons, where he announced the results of the 2020 Spending Review. Outlining measures designed to help the NHS maintain services as it recovers from the ongoing pandemic, the Chancellor announced £3 billion for recovery projects, including enhanced diagnostic testing, and greater capital spending to help replace outdated diagnostics equipment in hospitals. The NHS budg...
Read More
Nov 10, 2020
IMMY sõna Aspergillus Galactomannan Lateral Flow Assay recommended by the European Confederation of Medical Microbiology (ECMM) as a screening device in ventilated patients.
Read More
Oct 26, 2020
New sample collection kit enables convenient and safe collection, transportation and handling of pathogenic samples including COVID-19 and influenza
Read More
Oct 21, 2020
New Range of CE Certified Face Visors and Type II Masks with Introductory 10% Savings
Read More
Oct 19, 2020
Demystify chromogenic testing
Read More
Oct 13, 2020
New QuickGene Range for DNA & RNA Extraction- Now with Automated Option
Read More
Oct 06, 2020
Take Control and Save Time with Easy In-house Testing
Read More
Sep 30, 2020
Patented transport media manufactured by EKF Diagnostics can help to increase COVID-19 testing capacity
Read More
Sep 24, 2020
As demand for rapid testing continues to accelerate at an unprecedented level, our response to assisting testing on a global scale must be in place to support accurate, reliable and easy-to-use testing. The AbC-19™ COVID-19 antibody test developed by Abingdon Health and the UK-RTC, achieves 98.03% sensitivity and 99.5% specifically, will play an invaluable role in overcoming unpredicted rapid testing outcomes.Download the whitepaper to learn: How the body responds to SARS-CO...
Read More